PegIFNα/ribavirin/protease inhibitor combination in severe hepatitis C virus-Associated mixed cryoglobulinemia vasculitis

Journal of Hepatology

Volumn 62, Issue 1, 2016, Pages 24-30

  Saadoun, David ^a,b   Resche Rigon, Matthieu ^c   Pol, Stanislas ^d   Thibault, Vincent ^a   Blanc, François ^e   Pialoux, Gilles ^f   Karras, Alexandre ^g   Bazin Kara, Dorothée ^h   Cazorla, Cécile ⁱ   Vittecoq, Daniel ^j   Musset, Lucile ^a   Peltier, Julie ^f   Decaux, Olivier ^k   Ziza, Jean Marc ^l   Lambotte, Olivier ^m   Cacoub, Patrice ^a,b  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c SAINT LOUIS HOSPITAL   (France)

^d HÔPITAL NECKER ENFANTS MALADES   (France)

^e LAPEYRONIE HOSPITAL   (France)

^f HÔPITAL TENON   (France)

^g HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^h Ctr de Gerontologie des Hop Univ   (France)

ⁱ Department of Internal Medicine   (France)

^j HÔPITAL PAUL BROUSSE   (France)

^k SERVICE DE RHUMATOLOGIE   (France)

^l GROUPE HOSPITALIER DIACONESSES CROIX SAINT SIMON   (France)

^m BICÊTRE HOSPITAL   (France)

more..

Author keywords

Antiviral treatment; Hepatitis C virus; Mixed cryoglobulinemia; Treatment; Vasculitis

Indexed keywords

BOCEPREVIR; COMPLEMENT COMPONENT C4; CRYOGLOBULIN; ERYTHROPOIETIN; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; TELAPREVIR; ALPHA INTERFERON; ANTIVIRUS AGENT; DRUG CARRIER; MACROGOL DERIVATIVE; RECOMBINANT PROTEIN; VIRUS RNA;

ACUTE CHOLECYSTITIS; ACUTE PYELONEPHRITIS; ADULT; AGED; ANEMIA; ARTICLE; CLINICAL ARTICLE; COMPLEMENT BLOOD LEVEL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CRYOGLOBULINEMIA; CYTOPENIA; DEPRESSION; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; ERYTHROCYTE TRANSFUSION; FATIGUE; FEMALE; HEPATITIS C; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; INFECTION; MALE; NAUSEA; NEUTROPENIA; PNEUMONIA; PROSPECTIVE STUDY; PRURITUS; SKIN INFECTION; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; COMBINATION DRUG THERAPY; COMPLICATION; FOLLOW UP; GENETICS; HEPACIVIRUS; HEPATITIS C, CHRONIC; MIDDLE AGED; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; VASCULITIS; VIROLOGY;

AGED; ANTIVIRAL AGENTS; CRYOGLOBULINEMIA; DRUG CARRIERS; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; PROSPECTIVE STUDIES; RECOMBINANT PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RIBAVIRIN; RNA, VIRAL; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; VASCULITIS;

EID: 84918840101     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2014.08.015     Document Type: Article

References (32)

1. P.D. Gorevic, H.J. Kassab, Y. Levo, R. Kohn, M. Meltzer, and P. Prose Mixed cryoglobulinemia: clinical aspects and long-term follow-up of 40 patients Am J Med 69 1980 287 308
2. M. Ramos-Casals, J.H. Stone, M.C. Cid, and X. Bosch The cryoglobulinaemias Lancet 379 2012 348 360
3. J. Damoiseaux, and J.W. Cohen Tervaert Diagnostics and treatment of cryoglobulinaemia: it takes two to tango Clin Rev Allergy Immunol 2013 < http://www.ncbi.nlm.nih.gov/pubmed/24068540# >. [Epub ahead of print]
4. D. Saadoun, J. Sellam, P. Ghillani-Dalbin, R. Crecel, J.C. Piette, and P. Cacoub Increased risks of lymphoma and death among patients with non-hepatitis C virus-related mixed cryoglobulinemia Arch Intern Med 166 2006 2101 2108
5. M. Meltzer, E.C. Franklin, K. Elias, R.T. McCluskey, and N. Cooper Cryoglobulinemia - A clinical and laboratory study. II. Cryoglobulins with rheumatoid factor activity Am J Med 40 1966 837 856
6. V. Agnello, R.T. Chung, and L.M. Kaplan A role for hepatitis C virus infection in type II cryoglobulinemia N Engl J Med 327 1992 1490 1495
7. F. Dammacco, and D. Sansonno Therapy for hepatitis C virus-related cryoglobulinemic vasculitis N Engl J Med 369 2013 1035 1045
8. P. Cacoub, B. Terrier, and D. Saadoun Hepatitis C virus-induced vasculitis: therapeutic options Ann Rheum Dis 73 2013 24 30
9. D. Saadoun, M. Rosenzwajg, F. Joly, A. Six, F. Carrat, and V. Thibault Regulatory T-cell responses to low-dose interleukin-2 in HCV-induced vasculitis N Engl J Med 365 2011 2067 2077
10. S. De Vita, L. Quartuccio, M. Isola, C. Mazzaro, P. Scaini, and M. Lenzi A randomized controlled trial of rituximab for the treatment of severe cryoglobulinemic vasculitis Arthritis Rheum 64 2012 843 853
11. F. Dammacco, F.A. Tucci, G. Lauletta, P. Gatti, V. De Re, and V. Conteduca Pegylated interferon-Alpha, ribavirin, and rituximab combined therapy of hepatitis C virus-related mixed cryoglobulinemia: a long-term study Blood 116 2010 343 353
12. D. Saadoun, M. Resche Rigon, D. Sene, B. Terrier, A. Karras, and L. Perard Rituximab plus Peg-interferon-Alpha/ribavirin compared with Peg-interferon-Alpha/ribavirin in hepatitis C-related mixed cryoglobulinemia Blood 116 2010 326 334 quiz 504-325
13. M.C. Sneller, Z. Hu, and C.A. Langford A randomized controlled trial of rituximab following failure of antiviral therapy for hepatitis C virus-Associated cryoglobulinemic vasculitis Arthritis Rheum 64 2012 835 842
14. D. Saadoun, M. Resche-Rigon, V. Thibault, J.C. Piette, and P. Cacoub Antiviral therapy for hepatitis C virus - Associated mixed cryoglobulinemia vasculitis: a long-term followup study Arthritis Rheum 54 2006 3696 3706
15. M. Pietrogrande, S. De Vita, A.L. Zignego, P. Pioltelli, D. Sansonno, and S. Sollima Recommendations for the management of mixed cryoglobulinemia syndrome in hepatitis C virus-infected patients Autoimmun Rev 10 2011 444 454
16. C. Mazzaro, F. Franzin, P. Tulissi, E. Pussini, M. Crovatto, and G.S. Carniello Regression of monoclonal B-cell expansion in patients affected by mixed cryoglobulinemia responsive to alpha-interferon therapy Cancer 77 1996 2604 2613
17. N.L. Harris, E.S. Jaffe, J. Diebold, G. Flandrin, H.K. Muller-Hermelink, and J. Vardiman World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997 J Clin Oncol 17 1999 3835 3849
18. L. Musset, M.C. Diemert, F. Taibi, L. Thi Huong Du, P. Cacoub, and J.M. Leger Characterization of cryoglobulins by immunoblotting Clin Chem 38 1992 798 802
19. J.C. Brouet, J.P. Clauvel, F. Danon, M. Klein, and M. Seligmann Biologic and clinical significance of cryoglobulins. A report of 86 cases Am J Med 57 1974 775 788
20. D.W. Cockcroft, and M.H. Gault Prediction of creatinine clearance from serum creatinine Nephron 16 1976 31 41
21. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. The French METAVIR Cooperative Study Group Hepatology 20 1994 15 20
22. P. Lamprecht, F. Moosig, A. Gause, K. Herlyn, and W.L. Gross Birmingham vasculitis activity score, disease extent index and complement factor C3c reflect disease activity best in hepatitis C virus-Associated cryoglobulinemic vasculitis Clin Exp Rheumatol 18 2000 319 325
23. E.J. Bastyr 3rd, K.L. Price, and V. Bril Development and validity testing of the neuropathy total symptom score-6: questionnaire for the study of sensory symptoms of diabetic peripheral neuropathy Clin Ther 27 2005 1278 1294
24. A. Tarantino, M. Campise, G. Banfi, R. Confalonieri, A. Bucci, and A. Montoli Long-term predictors of survival in essential mixed cryoglobulinemic glomerulonephritis Kidney Int 47 1995 618 623
25. C. Ferri, M. Sebastiani, D. Giuggioli, M. Cazzato, G. Longombardo, and A. Antonelli Mixed cryoglobulinemia: demographic, clinical, and serologic features and survival in 231 patients Semin Arthritis Rheum 33 2004 355 374
26. D. Saadoun, M. Resche Rigon, V. Thibault, M. Longuet, S. Pol, and F. Blanc Peg-IFNalpha/ribavirin/protease inhibitor combination in hepatitis C virus associated mixed cryoglobulinemia vasculitis: results at week 24 Ann Rheum Dis 73 2013 831 837
27. C. Ferri, P. Cacoub, C. Mazzaro, D. Roccatello, P. Scaini, and M. Sebastiani Treatment with rituximab in patients with mixed cryoglobulinemia syndrome: results of multicenter cohort study and review of the literature Autoimmun Rev 11 2011 48 55
28. C. Hezode, H. Fontaine, C. Dorival, D. Larrey, F. Zoulim, and V. Canva Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890 J Hepatol 59 2013 434 441
29. K.E. Sherman, S.L. Flamm, N.H. Afdhal, D.R. Nelson, M.S. Sulkowski, and G.T. Everson Response-guided telaprevir combination treatment for hepatitis C virus infection N Engl J Med 365 2011 1014 1024
30. B.R. Bacon, S.C. Gordon, E. Lawitz, P. Marcellin, J.M. Vierling, and S. Zeuzem Boceprevir for previously treated chronic HCV genotype 1 infection N Engl J Med 364 2011 1207 1217
31. M.S. Sulkowski, D.F. Gardiner, M. Rodriguez-Torres, K.R. Reddy, T. Hassanein, and I. Jacobson Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection N Engl J Med 370 2014 211 221
32. G.T. Everson, K.D. Sims, M. Rodriguez-Torres, C. Hezode, E. Lawitz, and M. Bourliere Efficacy of an interferon- and ribavirin-free regimen of daclatasvir, asunaprevir, and BMS-791325 in treatment-naive patients with HCV genotype 1 infection Gastroenterology 146 2014 420 429